Figure 5

AZD2281 reverses resistance to Ico in vivo. Nude mouse HCC-827IR xenograft models were divided into four groups (10 mice/group) and treated for 14 days with 50 mg/kg Ico once daily and/or 30 mg/kg AZD2281 once daily by intraperitoneal injection. Tumors were resected on day 14. Tumor volumes were measured using a caliper (A). Tumor weights were measured on day 14 (B). Tumor tissues isolated from xenografts after treatment with Ico, AZD2281, or Ico + AZD2281 were subjected to western blot analysis (C) (Because of the films before imaging were cut, we couldn’t further provided fuller-length original blots). The data represent means ± SD of three independent experiments, *P < 0.05 versus untreated **P < 0.001 versus untreated. Tumor tissues isolated from xenografts after treatment with Ico, AZD2281, or Ico + AZD2281 were subjected to immunohistochemical stain of PARP1 (D) and p62 expression (E). The data shown represent the mean ± standard error, n = 10. *P < 0.05 versus the vehicle group.